Skip to content
Home
Team
Therapies
Overview/Pipeline
IC/BPS
Alenura®
Investor
News
Contact Us
Investor Login
  • March 19, 2025

Hyloris Announces Alenura® Positive IDMC Results

Home
/
Uncategorized
/
Hyloris Announces Alenura® Positive IDMC Results
Share Post:

The Independent Data Monitoring Committee (IDMC) Recommends Continuation of the Alenura Clinical Trial Following Interim Assessment. Read full Press Release.

PrevPrevious

Stay Connected

More Updates

Vaneltix Starts New Multiple Dose Clinical Trial

December 14, 2024, New Brunswick, NJ – Vaneltix Pharma, Inc. (“Vaneltix” or “the Company”), a specialty pharmaceutical company focused on the development of solutions for

December 14, 2024

Vaneltix planning to enroll subjects in new round of clinical trials

On Tuesday, February 21st 2023, Bound Brook, NJ – Vaneltix Pharma, Inc. (Formerly Urigen Pharmaceuticals, Inc.; “Vaneltix” or “the Company”), a specialty pharmaceutical company focused

February 21, 2023

Vaneltix enters joint development agreement with Hyloris Pharmaceuticals

On Thursday, December 16, Vaneltix entered into a Joint Development Agreement with Hyloris Pharmaceuticals NV, a Belgian pharmaceuticals company (“Hyloris”) with respect to Vaneltix’s Alenura™

December 21, 2021
Vaneltix Pharma, Inc.
317 George St., Ste. 400,
New Brunswick, NJ 08901
United States
Team
Therapies
Investor
News
Contact Us
2021 © Vaneltix. All rights reserved.
Privacy Policy
Privacy Policy
This website is created by Blink.